How effective is Mobocertinib?

Mobocertinib (Mobocertinib), as a new type of EGFR TKI drug, has shown excellent efficacy in the treatment of patients with non-small cell lung cancer positive for EGFR gene mutations. By inhibiting EGFR mutations and T790M mutations, it significantly extends survival, improves disease control rates, and effectively manages drug resistance while maintaining relatively good safety and tolerability. This drug provides patients with new treatment hope, improves their quality of life, and brings important medical progress to patients with advanced non-small cell lung cancer. However, please note that specific treatment decisions should be made by the physician based on the patient's specific situation.